Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Friday, March 21, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, a clinical stage gene editing company, is set to report its fourth quarter and fiscal year 2024 results on March 26, 2025. The company is known for its proprietary ARCUS platform, which focuses on developing in vivo gene editing therapies. Investors and stakeholders are keenly awaiting the results to assess the company's progress and future direction.
Price reaction · baseline $5.36 (2025-03-20 close) · hit pre-market · 2 other DTIL headline(s) in the window, move may be shared
day 0 close
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing its gene editing therapies.
  • The company is utilizing its innovative ARCUS platform.
  • The upcoming report may showcase significant progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Mar. 21, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today

Frequently Asked Questions

When will Precision BioSciences report its results?

Precision BioSciences will report its fourth quarter and fiscal year 2024 results on March 26, 2025.

What platform does Precision BioSciences use?

The company utilizes its proprietary ARCUS platform for gene editing therapies.

What type of therapies is Precision BioSciences developing?

Precision BioSciences is developing in vivo gene editing therapies, including gene elimination, insertion, and excision.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform fiscal year 2024
Last updated: Mar 21, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →